-
Mashup Score: 1The Multiple Myeloma Daily - 1 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Robert Z. Orlowski
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0EPd Triplet Therapy Boosts Survival in R/R MM Vs. Pd | ASH Clinical News | American Society of Hematology - 2 year(s) ago
Skip Nav Destination October 27, 2022 Treatment with elotuzumab plus pomalidomide/dexamethasone (EPd) resulted in a significant reduction in the risk of death compared with pomalidomide/dexamethasone (Pd) in patients with relapsed…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Second-Line Axi-Cel Is Cost-Effective in Relapsed/Refractory DLBCL | ASH Clinical News | American Society of Hematology - 2 year(s) ago
Skip Nav Destination September 26, 2022 Second-line axicabtagene ciloleucel (axi-cel) is cost-effective in cases of primary refractory or early relapsed and transplant-eligible diffuse large B-cell lymphoma (DLBCL), but the cost-effectiveness of…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Dr. Joshua Richter, a myeloma specialist, explains what it means to have relapsed myeloma or refractory myeloma.
Source: Patient Empowerment NetworkCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Teclistamab in Relapsed or Refractory Multiple Myeloma | NEJM - 2 year(s) ago
Original Article from The New England Journal of Medicine — Teclistamab in Relapsed or Refractory Multiple Myeloma
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Wolters Kluwer Health - 3 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
The latest The Multiple Myeloma Daily! https://t.co/xnce48BDGI Thanks to @OncologyTimes #multiplemyeloma #relapsed